By providing doses with pinpoint precision, proton therapy is painless, noninvasive and highly effective in treating tumors while minimizing damage to surrounding healthy cells. Due to the high price and huge scope of developing a proton therapy middle, there are only a handful of places in the U.S. Where patients can have the treatment. With recent less expensive options entering the market, Accelitech hopes to change that by using its existing model to focus on several proton therapy places over the next two years. The technology may be fresh, but our model for achievement remains the same, says Kerwin Brandt, President and CEO of Accelitech. Proton therapy is the next era of cancer treatment, and this project can be an exciting possibility to apply our proven, full-cycle management procedure to making this state-of-the-art technology open to sufferers on a broader scale.Related StoriesDisclosing genetic risk for CHD results in lower low-density lipoprotein cholesterolChildren with congenital heart disease and ADHD can reap the benefits of stimulant medicationsAngina in women linked with abnormal heart bloodstream flowDr. Qian received the prize on her behalf findings that non-muscle mass cells that normally type the architectural support for the heart could be reprogrammed into defeating heart muscle mass cells. This reprogramming may allow scientists to transform non-defeating scar tissue formation resulting from cardiovascular disease – – and that was previously regarded as irreparable – – into beating tissue once again.